TERN
Terns Pharmaceuticals Inc.
$6.96
-$0.11(-1.56%)
60
Overall
--
Value
90
Tech
31
Quality
Market Cap
$634.46M
Volume
912.39K
52W Range
$1.87 - $11.40
Target Price
$20.00
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $1.0M | -- | -- | -- | ||
| Total Revenue | $1.0M | -- | -- | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | $1.0M | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $50.9M | $62.0M | $102.6M | $101.9M | ||
| Research & Development | $31.3M | $39.6M | $63.5M | $70.1M | ||
| Research Expense | $31.3M | $39.6M | $63.5M | $70.1M | ||
| Selling, General & Administrative | $19.5M | $22.4M | $39.1M | $31.8M | ||
| General & Administrative Expenses | $19.5M | $22.4M | $39.1M | $31.8M | ||
| Salaries & Wages | -- | -- | $25.5M | $15.6M | ||
| Depreciation & Amortization | $500.0K | $500.0K | $300.0K | $300.0K | ||
| Depreciation & Amortization | $500.0K | $500.0K | $300.0K | $300.0K | ||
| Other Operating Expenses | $-451.0K | $-706.0K | $-1.3M | $-1.5M | ||
| OPERATING INCOME | ||||||
| Operating income | $-49.9M | $-62.0M | $-102.6M | $-101.9M | ||
| EBITDA | $-48.3M | $-58.9M | $-101.7M | $-89.8M | ||
| NON-OPERATING ITEMS | ||||||
| Gain on Sale of Securities | $170.0K | $2.1M | $12.9M | $13.3M | ||
| Other Income/Expense | $-210.0K | $-2.0M | $-12.6M | $-13.3M | ||
| Other Special Charges | $40.0K | $-68.0K | $-314.0K | $-11.0K | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-49.6M | $-60.0M | $-102.6M | $-88.6M | ||
| Pre-Tax Income | $-49.6M | $-60.0M | $-90.0M | $-88.6M | ||
| INCOME TAX | ||||||
| Tax Provision | $508.0K | $358.0K | $239.0K | $260.0K | ||
| NET INCOME | ||||||
| Net Income | $-50.2M | $-60.3M | $-90.2M | $-88.9M | ||
| Net Income (Continuing Operations) | $-50.2M | $-60.3M | $-90.2M | $-88.9M | ||
| Net Income (Discontinued Operations) | $-50.2M | $-60.3M | $-90.2M | $-88.9M | ||
| Net Income (Common Stockholders) | $-50.2M | $-60.3M | $-90.2M | $-88.9M | ||
| Normalized Income | $-39.2M | $-47.4M | -- | $-87.7M | ||
| TOTALS | ||||||
| Total Expenses | $50.9M | $62.0M | $102.6M | $101.9M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $22.7M | $36.0M | $71.3M | $79.5M | ||
| Average Shares Outstanding (Diluted) | $22.7M | $36.0M | $71.3M | $79.5M | ||
| Shares Outstanding | $25.3M | $56.7M | $64.7M | $87.3M | ||
| Basic EPS | $-2.21 | $-1.67 | $-1.27 | $-1.12 | ||
| Basic EPS (Continuing Operations) | $-2.21 | $-1.67 | $-1.27 | $-1.12 | ||
| Diluted EPS | $-2.21 | $-1.67 | $-1.27 | $-1.12 | ||
| Diluted EPS (Continuing Operations) | -- | $-1.67 | $-1.27 | $-1.12 | ||
| OTHER METRICS | ||||||
| Other Gand A | $19.5M | $22.4M | $39.1M | $31.8M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TERN | $6.96 | -1.6% | 912.39K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Terns Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW